244 related articles for article (PubMed ID: 34802051)
21. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Pennipede D; Mohyuddin GR; Hawkins R; Ganguly S; Shune L; Ahmed N; Mohan M; Cui W; Mahmoudjafari Z; McGuirk J; Atrash S; Abdallah AO
Eur J Haematol; 2021 Dec; 107(6):602-608. PubMed ID: 34378251
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
[TBL] [Abstract][Full Text] [Related]
24. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.
Schroeder MA; Fiala MA; Huselton E; Cardone MH; Jaeger S; Jean SR; Shea K; Ghobadi A; Wildes T; Stockerl-Goldstein KE; Vij R
Clin Cancer Res; 2019 Jul; 25(13):3776-3783. PubMed ID: 30952640
[TBL] [Abstract][Full Text] [Related]
25. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL; Pascucci N; Smith DD; Orlowski RZ; Durie BG
Blood; 2015 Nov; 126(20):2284-90. PubMed ID: 26384354
[TBL] [Abstract][Full Text] [Related]
26. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.
Gasparetto C; Lentzsch S; Schiller G; Callander N; Tuchman S; Chen C; White D; Kotb R; Sutherland H; Sebag M; Baljevic M; Bensinger W; LeBlanc R; Venner C; Bahlis N; Rossi A; Biran N; Sheehan H; Saint-Martin JR; Van Domelen D; Kai K; Shah J; Shacham S; Kauffman M; Lipe B
EJHaem; 2021 Feb; 2(1):56-65. PubMed ID: 35846104
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R
Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245
[TBL] [Abstract][Full Text] [Related]
28. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Chari A; Larson S; Holkova B; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Valent J; Lunning M; Usmani SZ; Anderson LD; Chang L; Lee Y; Pak Y; Salman Z; Graef T; Bilotti E; Chhabra S
Leuk Lymphoma; 2018 Nov; 59(11):2588-2594. PubMed ID: 29616843
[TBL] [Abstract][Full Text] [Related]
30. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
[TBL] [Abstract][Full Text] [Related]
31. Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Sherbenou D; Stalker M; Forsberg P; Mark TM
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e630-e634. PubMed ID: 33863694
[No Abstract] [Full Text] [Related]
32. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Venner CP; LeBlanc R; Sandhu I; White D; Belch AR; Reece DE; Chen C; Dolan S; Lalancette M; Louzada M; Kew A; McCurdy A; Monteith B; Reiman T; McDonald G; Sherry M; Gul E; Chen BE; Hay AE
Am J Hematol; 2021 May; 96(5):552-560. PubMed ID: 33650179
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Berdeja JG; Gregory TK; Faber EA; Hart LL; Mace JR; Arrowsmith ER; Flinn IW; Matous JV
Am J Hematol; 2021 Apr; 96(4):428-435. PubMed ID: 33421178
[TBL] [Abstract][Full Text] [Related]
34. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
Sugiura I; Suzuki K; Ri M; Chou T; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Iida S
Int J Hematol; 2020 Jan; 111(1):57-64. PubMed ID: 31664647
[TBL] [Abstract][Full Text] [Related]
35. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
36. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
38. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
39. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Richardson PG; Zimmerman TM; Hofmeister CC; Talpaz M; Chanan-Khan AA; Kaufman JL; Laubach JP; Chauhan D; Jakubowiak AJ; Reich S; Trikha M; Anderson KC
Blood; 2016 Jun; 127(22):2693-700. PubMed ID: 27009059
[TBL] [Abstract][Full Text] [Related]
40. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
